Immunology of Injectable Collagen in Human Subjects

FRANK DELUSTRO, VICTORIA MACKINNON, Neil Swanson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Abstract. Associated with the use of Zyderm Collagen Implant (ZCI) for soft tissue augmentation, the rate of localized hypersensitivity reactions to the initial test injection of ZCI range from 3.0–3.5% in the literature, and subsequent reactions to treatment have reportedly ranged from 1.1–5.0%. The inflammatory symptoms to the Collagen Test Implant occur within 72 hours in 2% of those injected, indicating a preexisting sensitivity to bovine collagen in this healthy population. Most adverse treatment reactions follow the first treatment and after injection of <5 ml of collagen. Furthermore, antibodies against collagen in sera of subjects reporting localized symptoms of hypersensitivity at test or treatment sites are specific for bovine interstitial collagens and show no cross‐reactivity with human collagens. Thus, immunologic reaction to ZCI results in antibovine collagen antibodies and localized inflammatory symptoms in those few subjects who experience hypersensitivity to test or treatment. Glutaraldehyde cross‐linked Zyplast Implant (ZI), has demonstrated a lower incidence of hypersensitivity reactions than ZCI. In examining patients tested with ZI or treated for intradermal and subdermal indications, we have experienced only 7 hypersensitivity reactions at test sites of ZI, out of 803 tested subjects, and only 3 reactions among 498 treated patients. Therefore, ZI appears to induce a lower incidence of hypersensitivity reactions than ZCI in man. 1988 American Society for Dermatologic Surgery, Inc.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalJournal of Dermatologic Surgery and Oncology
Volume14
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Allergy and Immunology
Collagen
Injections
Hypersensitivity
Dermatologic Surgical Procedures
Therapeutics
Antibodies
Incidence
Glutaral

ASJC Scopus subject areas

  • Oncology
  • Dermatology

Cite this

Immunology of Injectable Collagen in Human Subjects. / DELUSTRO, FRANK; MACKINNON, VICTORIA; Swanson, Neil.

In: Journal of Dermatologic Surgery and Oncology, Vol. 14, 1988, p. 49-55.

Research output: Contribution to journalArticle

DELUSTRO, FRANK ; MACKINNON, VICTORIA ; Swanson, Neil. / Immunology of Injectable Collagen in Human Subjects. In: Journal of Dermatologic Surgery and Oncology. 1988 ; Vol. 14. pp. 49-55.
@article{05ac0bb59f274d8a9a9cb8fbe09f6457,
title = "Immunology of Injectable Collagen in Human Subjects",
abstract = "Abstract. Associated with the use of Zyderm Collagen Implant (ZCI) for soft tissue augmentation, the rate of localized hypersensitivity reactions to the initial test injection of ZCI range from 3.0–3.5{\%} in the literature, and subsequent reactions to treatment have reportedly ranged from 1.1–5.0{\%}. The inflammatory symptoms to the Collagen Test Implant occur within 72 hours in 2{\%} of those injected, indicating a preexisting sensitivity to bovine collagen in this healthy population. Most adverse treatment reactions follow the first treatment and after injection of <5 ml of collagen. Furthermore, antibodies against collagen in sera of subjects reporting localized symptoms of hypersensitivity at test or treatment sites are specific for bovine interstitial collagens and show no cross‐reactivity with human collagens. Thus, immunologic reaction to ZCI results in antibovine collagen antibodies and localized inflammatory symptoms in those few subjects who experience hypersensitivity to test or treatment. Glutaraldehyde cross‐linked Zyplast Implant (ZI), has demonstrated a lower incidence of hypersensitivity reactions than ZCI. In examining patients tested with ZI or treated for intradermal and subdermal indications, we have experienced only 7 hypersensitivity reactions at test sites of ZI, out of 803 tested subjects, and only 3 reactions among 498 treated patients. Therefore, ZI appears to induce a lower incidence of hypersensitivity reactions than ZCI in man. 1988 American Society for Dermatologic Surgery, Inc.",
author = "FRANK DELUSTRO and VICTORIA MACKINNON and Neil Swanson",
year = "1988",
doi = "10.1111/j.1524-4725.1988.tb04040.x",
language = "English (US)",
volume = "14",
pages = "49--55",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Immunology of Injectable Collagen in Human Subjects

AU - DELUSTRO, FRANK

AU - MACKINNON, VICTORIA

AU - Swanson, Neil

PY - 1988

Y1 - 1988

N2 - Abstract. Associated with the use of Zyderm Collagen Implant (ZCI) for soft tissue augmentation, the rate of localized hypersensitivity reactions to the initial test injection of ZCI range from 3.0–3.5% in the literature, and subsequent reactions to treatment have reportedly ranged from 1.1–5.0%. The inflammatory symptoms to the Collagen Test Implant occur within 72 hours in 2% of those injected, indicating a preexisting sensitivity to bovine collagen in this healthy population. Most adverse treatment reactions follow the first treatment and after injection of <5 ml of collagen. Furthermore, antibodies against collagen in sera of subjects reporting localized symptoms of hypersensitivity at test or treatment sites are specific for bovine interstitial collagens and show no cross‐reactivity with human collagens. Thus, immunologic reaction to ZCI results in antibovine collagen antibodies and localized inflammatory symptoms in those few subjects who experience hypersensitivity to test or treatment. Glutaraldehyde cross‐linked Zyplast Implant (ZI), has demonstrated a lower incidence of hypersensitivity reactions than ZCI. In examining patients tested with ZI or treated for intradermal and subdermal indications, we have experienced only 7 hypersensitivity reactions at test sites of ZI, out of 803 tested subjects, and only 3 reactions among 498 treated patients. Therefore, ZI appears to induce a lower incidence of hypersensitivity reactions than ZCI in man. 1988 American Society for Dermatologic Surgery, Inc.

AB - Abstract. Associated with the use of Zyderm Collagen Implant (ZCI) for soft tissue augmentation, the rate of localized hypersensitivity reactions to the initial test injection of ZCI range from 3.0–3.5% in the literature, and subsequent reactions to treatment have reportedly ranged from 1.1–5.0%. The inflammatory symptoms to the Collagen Test Implant occur within 72 hours in 2% of those injected, indicating a preexisting sensitivity to bovine collagen in this healthy population. Most adverse treatment reactions follow the first treatment and after injection of <5 ml of collagen. Furthermore, antibodies against collagen in sera of subjects reporting localized symptoms of hypersensitivity at test or treatment sites are specific for bovine interstitial collagens and show no cross‐reactivity with human collagens. Thus, immunologic reaction to ZCI results in antibovine collagen antibodies and localized inflammatory symptoms in those few subjects who experience hypersensitivity to test or treatment. Glutaraldehyde cross‐linked Zyplast Implant (ZI), has demonstrated a lower incidence of hypersensitivity reactions than ZCI. In examining patients tested with ZI or treated for intradermal and subdermal indications, we have experienced only 7 hypersensitivity reactions at test sites of ZI, out of 803 tested subjects, and only 3 reactions among 498 treated patients. Therefore, ZI appears to induce a lower incidence of hypersensitivity reactions than ZCI in man. 1988 American Society for Dermatologic Surgery, Inc.

UR - http://www.scopus.com/inward/record.url?scp=84990634391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990634391&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.1988.tb04040.x

DO - 10.1111/j.1524-4725.1988.tb04040.x

M3 - Article

AN - SCOPUS:84990634391

VL - 14

SP - 49

EP - 55

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

ER -